How many clinical trials are tracked of mRNA-1273?

15 trials are tracked, 9 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

mRNA-1273

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of mRNA-1273

15 trials tracked of mRNA-1273: 9 in phase 3 or 4 and 9 with published results. The most-cited published study has 648 citations.

15Trials tracked

9Phase 3 & 4

0Recruiting

9With published results

Phase distribution

Phase 4 1 Phase 3 8 Phase 2 4 Phase 1 2

Phase 3 A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants Completed · 648 cited
Phase 3 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 Completed · 371 cited
Phase 3 A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age Completed · 175 cited
Phase 3 A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 Completed · 53 cited
Phase 3 A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine Completed · 36 cited
Phase 3 A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants Completed · 9 cited

Show 9 more trials

Phase 3 A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 Completed · 9 cited
Phase 4 Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) Completed · 7 cited
Phase 3 Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) Completed · 3 cited
Phase 2 A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old Completed
Phase 2 A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters Completed
Phase 2 COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) Completed
Phase 2 Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines Completed
Phase 1 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) Completed
Phase 1 Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.